ALLO

MKT CAP:$564M

Allogene Therapeutics, Inc.

Market Cap

$564M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$2.31+$0.96 (+71.11%)

Apr 24, 2026

Company Details

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an all...

CEO

David D. Chang

IPO Date

Oct 11, 2018

Website

www.allogene.com

Key Metrics TTM

Revenue

$0

-100.0% YoY

Net Income

-$191M

EPS (Diluted)

-$0.87

Free Cash Flow

-$150M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 12, 2026

PENDING

FY 2025

Mar 12, 2026

$0-100.0%EPS -$0.87

Q4 2025

Mar 12, 2026

$0EPS -$0.17

Q3 2025

Nov 6, 2025

$0EPS -$0.19

Q2 2025

Aug 13, 2025

$0EPS -$0.23

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q4 21	$51.0K	$51.0K	-$74M
Q1 22	$61.0K	$61.0K	-$80M
Q2 22	$86.0K	$86.0K	-$77M
Q3 22	$49.0K	$49.0K	-$82M
Q4 22	$47.0K	$47.0K	-$96M
Q1 23	$30.0K	$30.0K	-$99M
Q2 23	$22.0K	$22.0K	-$81M
Q4 23	-$44.0K	-$44.0K	-$85M
Q1 24	$22.0K	-$4M	-$70M
Q2 24	$0	$0	-$71M
Q3 24	$0	$0	-$72M
Q4 24	$0	-$3M	-$60M
Q1 25	$0	-$3M	-$65M
Q2 25	$0	$0	-$57M
Q3 25	$0	-$31M	-$45M
Q4 25	$0	-$3M	-$42M

Valuation

Quarter	P/S	P/E
Q4 21	56.2x	—
Q1 22	6571.3x	—
Q2 22	6791.9x	—
Q3 22	6227.0x	—
Q4 22	3527.8x	—
Q1 23	3524.5x	—
Q2 23	5618.5x	—
Q4 23	9624.9x	—
Q1 24	27743.9x	—
Q2 24	—	—
Q3 24	—	—
Q4 24	20100.1x	—
Q1 25	—	—
Q2 25	—	—
Q3 25	—	—
Q4 25	—	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 21	-$45M	-$46M
Q1 22	-$68M	-$70M
Q2 22	-$43M	-$44M
Q3 22	-$48M	-$48M
Q4 22	-$62M	-$64M
Q1 23	-$67M	-$68M
Q2 23	-$62M	-$62M
Q4 23	-$54M	-$54M
Q1 24	-$56M	-$56M
Q2 24	-$64M	-$64M
Q3 24	-$44M	-$45M
Q4 24	-$37M	-$37M
Q1 25	-$53M	-$53M
Q2 25	-$39M	-$39M
Q3 25	-$30M	-$30M
Q4 25	-$28M	-$28M

Capital Expenditures

Quarter	CapEx
Q4 21	$736.0K
Q1 22	$2M
Q2 22	$1M
Q3 22	$223.0K
Q4 22	$2M
Q1 23	$1M
Q2 23	$288.0K
Q4 23	$181.0K
Q1 24	$8.0K
Q2 24	$0
Q3 24	$429.0K
Q4 24	$257.0K
Q1 25	$99.0K
Q2 25	$44.0K
Q3 25	$243.0K
Q4 25	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 21	—	+6.6%
Q1 22	-99.8%	+11.9%
Q2 22	+95.5%	+7.9%
Q3 22	+0.0%	+6.2%
Q4 22	-7.8%	+30.4%
Q1 23	-50.8%	+23.8%
Q2 23	-74.4%	+5.1%
Q4 23	-189.8%	+3.1%
Q1 24	-53.2%	-27.9%
Q2 24	-100.0%	-27.9%
Q3 24	-100.0%	-10.9%
Q4 24	+100.0%	-28.9%
Q1 25	-100.0%	-6.2%
Q2 25	—	-20.5%
Q3 25	—	-37.4%
Q4 25	—	-29.9%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 21	$0	0.0%
Q1 22	$0	0.0%
Q2 22	$0	0.0%
Q3 22	$21M	43159.2%
Q4 22	$0	0.0%
Q1 23	$19M	62566.7%
Q2 23	$17M	75427.3%
Q4 23	$15M	—
Q1 24	$12M	54200.0%
Q2 24	$14M	—
Q3 24	$13M	—
Q4 24	$13M	—
Q1 25	$12M	—
Q2 25	$9M	—
Q3 25	$9M	—
Q4 25	$8M	—

OpEx Breakdown

Quarter	R&D	G&A
Q4 21	$54M	$20M
Q1 22	$60M	$20M
Q2 22	$57M	$20M
Q3 22	$64M	$19M
Q4 22	$75M	$21M
Q1 23	$80M	$19M
Q2 23	$62M	$19M
Q4 23	$55M	$17M
Q1 24	$52M	$17M
Q2 24	$50M	$16M
Q3 24	$45M	$16M
Q4 24	$45M	$16M
Q1 25	$50M	$15M
Q2 25	$40M	$14M
Q3 25	$31M	$14M
Q4 25	$29M	$14M

Revenue Segments

Quarter	License
Q1 25	$5M
Q2 25	$5M
Q3 25	$5M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$85M	$365M	$449M
Q2 22	$96M	$394M	$490M
Q3 22	$74M	$478M	$552M
Q4 22	$62M	$455M	$517M
Q1 23	$110M	$361M	$471M
Q2 23	$155M	$337M	$492M
Q3 23	$69M	$396M	$466M
Q4 23	$83M	$366M	$449M
Q1 24	$51M	$334M	$385M
Q2 24	$171M	$274M	$445M
Q3 24	$51M	$240M	$292M
Q4 24	$75M	$217M	$292M
Q1 25	$42M	$238M	$280M
Q2 25	$52M	$221M	$273M
Q3 25	$38M	$214M	$252M
Q4 25	$52M	$199M	$250M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q4 21	139M	+1.6%	+7.2%
Q1 22	141M	+1.6%	+7.0%
Q2 22	143M	+1.4%	+6.3%
Q3 22	144M	+0.2%	+4.8%
Q4 22	144M	+0.3%	+3.6%
Q1 23	145M	+0.3%	+2.3%
Q2 23	147M	+1.5%	+2.4%
Q4 23	168M	+14.7%	+17.2%
Q1 24	169M	+0.5%	+17.3%
Q2 24	190M	+12.4%	+31.4%
Q3 24	209M	+10.1%	+42.5%
Q4 24	211M	+0.7%	+25.1%
Q1 25	215M	+2.3%	+27.3%
Q2 25	219M	+1.7%	+15.2%
Q3 25	222M	+1.4%	+6.1%
Q4 25	221M	-0.6%	+4.8%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q4 21	$165	310
Q1 22	$197	310
Q2 22	$277	310
Q3 22	$158	310
Q4 22	$130	361
Q1 23	$83	361
Q2 23	$61	361
Q4 23	-$189	233
Q1 24	$94	233
Q2 24	$0	233
Q3 24	$0	233
Q4 24	$0	226
Q1 25	$0	226
Q2 25	$0	226
Q3 25	$0	226
Q4 25	$0	200K

Revenue / Employee